The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for SwiftSight Body Composition, expanding AIRS Medical’s quantitative MRI platform into advanced body composition analysis. The regulatory milestone paves the way for imaging organizations to integrate automated AI analysis into routine MRI workflows, offering standardized measurements of muscle, adipose tissue, and liver fat without utilizing ionizing radiation.
As healthcare providers increasingly look beyond traditional metrics like body weight and body mass index (BMI)—which often fail to reflect how fat and muscle are distributed throughout the human body—new quantitative diagnostic tools are entering the market. AIRS Medical’s regulatory clearance marks a direct expansion of its quantitative MRI capabilities, creating new pathways for preventive health, weight management, and longevity tracking.
What Changed
The U.S. FDA cleared SwiftSight Body Composition, allowing AIRS Medical to deploy its quantitative MRI platform for deep body composition analysis. Under the cleared parameters, the solution requires an MRI scan time of less than five minutes, followed immediately by automated AI analysis.
Measurements generated by the system are automatically benchmarked against age- and sex-matched reference populations. These metrics are then compiled into a standardized Body Composition Report. According to company announcements, SimonMed Imaging will serve as the first customer to deploy SwiftSight Body Composition across its operations.
Technical and Business Explanation
SwiftSight Body Composition relies on AI-powered MRI analysis to quantify several core physiological components. The software measures muscle and adipose tissue, encompassing visceral fat, subcutaneous fat, abdominal and thigh muscle, muscle quality, bilateral muscle balance, and liver fat.
Liver fat quantification utilizes proton density fat fraction (PDFF) combined with automated region-of-interest measurements and visual mapping. Because the underlying MRI exam does not use ionizing radiation, patients can safely undergo repeat quantitative assessments over time.
“Body composition becomes more meaningful when people can track change over time, and that requires an exam that is fast and practical to repeat,” said Jina Park, Chief Strategy Officer at AIRS Medical. “That is why we built SwiftSight Body Composition around a scan of less than five minutes. Whether the goal is preventive health, weight management or longevity, we want people who are taking a more active role in their health to have a quantitative measurement they can return to over time.”
From an operational standpoint, the automated AI analysis reduces manual measurement needs. This helps imaging organizations deploy consistent quantitative body composition across multiple locations without adding operational complexity.
“The next phase of MRI is not just better images, but standardized quantitative information that can scale across an imaging organization,” said Ajit Shankaranarayanan, PhD, Chief Product Officer at AIRS Medical. “SwiftSight Body Composition is part of that shift. By automating the analysis of muscle, adipose tissue and liver fat, we are making advanced quantitative assessment easier to integrate into routine MRI workflows and creating a foundation for additional measurement capabilities across the SwiftSight platform.”
Business Implications and Sector Impact
The clearance carries notable commercial implications for imaging centers and radiology groups. According to company claims, SwiftSight Body Composition allows imaging organizations to standardize body composition analysis, scale operations smoothly across existing MRI infrastructure, and generate new revenue opportunities by tapping into growing consumer demand for preventive health and longevity tracking.
Traditional weight and BMI metrics frequently fall short of providing a complete clinical picture. By offering detailed insights into visceral fat versus subcutaneous fat, alongside muscle quality and bilateral muscle balance, imaging providers can package these reports for wellness, specialized weight management, and longitudinal health programs.
Risks, Limitations, and Future Roadmap
While the 510(k) clearance enables immediate commercial deployment starting with SimonMed Imaging, broader adoption depends on integration into existing clinical IT workflows and reimbursement landscapes. Furthermore, while the current clearance covers core body composition metrics, future platform capabilities carry distinct timelines.
AIRS Medical has outlined plans to expand the SwiftSight platform with diffusion tensor imaging (DTI) slated for November 2026, followed by quantitative joint applications in 2027. However, exact commercial launch schedules and performance capabilities for these upcoming roadmap features remain unverified beyond company expectations.
What to Watch Next
Industry observers will monitor the initial rollout at SimonMed Imaging to evaluate clinical throughput, workflow integration speed, and patient adoption rates for the sub-five-minute MRI exams. Additional milestones to watch include the execution of the November 2026 DTI expansion and the 2027 quantitative joint applications roadmap as AIRS Medical continues to build out its broader quantitative imaging portfolio.